Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Line Treatment ◽

First Line ◽

HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2019.7474 ◽

2020 ◽

Vol 18 (3.5) ◽

pp. HSR20-096

Author(s):

Frank Xiaoqing Liu ◽

Kirstin Heinrich ◽

Catarina Neves ◽

Ying Zheng ◽

Adam Kasle

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Line Treatment ◽

First Line ◽

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Renal Cell ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2015.1058359 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1915-1927 ◽

Cited By ~ 15

Author(s):

James Larkin ◽

Abby Paine ◽

Grace Foley ◽

Stephen Mitchell ◽

Connie Chen

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Line Treatment ◽

First Line ◽

Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma

Current Medical Research and Opinion ◽

10.1080/03007995.2020.1799771 ◽

2020 ◽

Vol 36 (9) ◽

pp. 1507-1517

Author(s):

Arielle G. Bensimon ◽

Yichen Zhong ◽

Umang Swami ◽

Allison Briggs ◽

Joshua Young ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Correction to: “Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use”

Drugs & Therapy Perspectives ◽

10.1007/s40267-019-00613-z ◽

2019 ◽

Vol 35 (4) ◽

pp. 200-200

Author(s):

Katherine A. Lyseng-Williamson

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use

Drugs & Therapy Perspectives ◽

10.1007/s40267-018-0547-6 ◽

2018 ◽

Vol 34 (10) ◽

pp. 457-465 ◽

Cited By ~ 4

Author(s):

Katherine A. Lyseng-Williamson

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)

Annals of Oncology ◽

10.1093/annonc/mdw373.71 ◽

2016 ◽

Vol 27 ◽

pp. vi293 ◽

Cited By ~ 2

Author(s):

R.J. Motzer ◽

T. Choueiri ◽

J. Larkin ◽

L. Albiges ◽

J.B. Haanen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Costs Associated with Health Care Resource Use in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Treatment with Pazopanib Versus Sunitinib

Value in Health ◽

10.1016/j.jval.2014.03.452 ◽

2014 ◽

Vol 17 (3) ◽

pp. A77-A78

Author(s):

M.D. Hackshaw ◽

R.N. Hansen ◽

S.P. Nagar ◽

B. Arondekar ◽

K.C. Deen ◽

...

Keyword(s):

Health Care ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Resource Use ◽

Renal Cell ◽

Health Care Resource ◽

Line Treatment ◽

First Line ◽

PCN10 Targeted Therapy (TT) for First Line Treatment of Advanced Renal Cell Carcinoma (RCC): An Indirect Comparison Meta-Analysis (ICMA)

Value in Health ◽

10.1016/j.jval.2012.03.1128 ◽

2012 ◽

Vol 15 (4) ◽

pp. A209

Author(s):

W. Matheus ◽

M.A. Duran ◽

O.A.C. Clark ◽

A. Kumar ◽

U. Ferreira ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Indirect Comparison ◽

Line Treatment ◽

First Line ◽

LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2105 ◽

2021 ◽

Vol 32 ◽

pp. S1304-S1305

Author(s):

N.S. Vasudev ◽

G. Ainsworth ◽

S. Brown ◽

L. Pickering ◽

T.S. Waddell ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽